Abstract: The present invention provides a method for identifying a T6SS effector as well as the corresponding T6SS effector immunity protein. The present invention also provides a composition and uses there of that include T6SS effector and T6SS effector immunity protein that are identified using the method of the invention. In particular, the method of the invention utilizes a conserved domain sequence of T6SS of Gram-negative bacteria to identify a T6SS effector and its corresponding immunity protein.
Abstract: Embodiments of systems and methods for GNSS and INS integration are described In an embodiment, the method includes receiving a GNSS signal from a GNSS signal source at an antenna coupled to a GNSS receiver. The method may also include generating GNSS data in response to the GNSS signal. Additionally, the method may include communicating the GNSS data to an INS system. The method may also include generating an IMU signal with an IMU sensor. The method may further include generating IMU data in response to the IMU signal. Also, the method may include integrating the IMU data with the GNSS data in a navigation processing unit of an INS. The method may further include generating INS data in response to the integrated IMU data and the GNSS data.
Abstract: This disclosure provides therapeutic compositions and methods for treating multiple sclerosis or a multiple sclerosis-related disorder in a subject in need thereof comprising administering an effective amount of an antigen-MHC-nanoparticle complex to the subject, wherein the antigen is a multiple sclerosis-related antigen.
Abstract: Embodiments of wearable electronic devices in game play applications are described. In an embodiment a method may include receiving a signal characteristic of movement of a MEMS inertial sensor (202) configured to generate data in response to movement of a human foot. The method may also include processing the signal received from the MEMS inertial sensor (202), in a processing device (203), to generate a command input for an application processing device (206, 208, 210, 212). Additionally, the method may include communicating the command input to the application processing device (206, 208, 210, 212) for control of an application hosted on the application processing device.
Abstract: A control circuit for an image sensor includes an active reset control circuit configured to perform an active reset of a light flux-dependent node (such as a photodetector) of a pixel of the image sensor using an amplifier which is also used for readout of the photodetector. The control circuit further includes a readout control circuit configured to maintain a readout configuration of the amplifier during the active reset.
Abstract: The invention provides methods treating pain by inhibiting a Cav3.2 channel expression or function, including the use of contacting said channel in situ with an inhibitor of USP5 or an inhibitor of the interaction between Cav3.2 and USP5.
Type:
Grant
Filed:
September 17, 2013
Date of Patent:
June 12, 2018
Assignee:
UTI LIMITED PARTNERSHIP
Inventors:
Agustin Garcia-Caballero, Vinicius Gadotti, Norbert Weiss, Gerald W. Zamponi
Abstract: This disclosure pertains to stimulation and monitoring devices for in utero cognitive stimulation of and interaction with developing fetuses by synthesizing sounds and sound patterns derived from movements of the fetuses' bodies and appendages. The exemplary stimulation and monitoring devices comprise arrays of sensors positionable above and/or the sides of the womb for detecting and recording movements of the fetus's body and appendages, one or more speakers, a microprocessor, controls, and optionally one or more light-emitting components. The collected movement data may be processed by a synthesizer for production of sound patterns and light patterns that are correlated with the movement data. The sound patterns and light patterns produced by the synthesizer may be transmitted through the speakers and the light-emitting components toward and into the womb to provide the development fetus with immediate cognitive stimulation in response to the movements of their body and appendages.
Abstract: Compositions and methods for reducing the level of prions in a prion-infected cells or host by exposing prion infected cells, tissues and organs to AR-12 and the AR-12 analog AR-14 to reduce the prion level by at least about 90%.
Type:
Grant
Filed:
February 28, 2017
Date of Patent:
May 22, 2018
Assignees:
OHIO STATE INNOVATION FOUNDATION, UTI LIMITED PARTNERSHIP
Inventors:
Hermann M. Schaetzl, Basant Abdulrahman, Sabine Gilch, Alexander Zukiwski, Stefan Proniuk
Abstract: Embodiments of custom test systems for leveraging centrally located subject matter expert recommendations in personnel selection are presented. In an embodiment, a method includes storing a predetermined set of personnel tests in a database. The method may also include determining a correlation indicator, the correlation indicator defining a strength of correlation between an aspect of at least one of the personnel tests and a measure of job performance, wherein the correlation indicator is determined in response to validation information provided by one or more subject matter experts. Additionally, such a method may include automatically building a custom personnel evaluation in response to the correlation indicator.
Abstract: The present application provides an amphiphilic cyclodextrin-based compound of the formula I: R-G-D-A (I) wherein R is one or more hydrophilic groups; G is one or more linkers; D is a cyclodextrin, and A is one or more aliphatic groups. In certain embodiments, the hydrophilic group is a sugar such as lactose, the linker comprises —(CHR?CH2O)n— where R? is H or is an alkyl group substituted with —(CHR?CH2O)n— where n is 1 to 20, typically n=4; the cyclodextrin is a ?-cyclodextrin comprising 7 subunits, and the aliphatic groups are C6 alkyl groups. The compound can be used to enhance water solubility, bioavailability, cellular uptakes of active ingredients used in medicines, cosmetics and foods and other products, for detection, removal and immobilization of pathogenic organisms, toxins, and autoantibodies, and biomarkers on solid matrix, or for molecular biological techniques, such as ELISA, for example.
Abstract: Noise parameters are used to characterize noise performance of linear devices, such as amplifiers. Such noise parameters have not been used for frequency conversion devices, such as mixers. Direct measurements of single-side-band noise figures are accurately represented by the measured noise parameters, which fully characterize the noise figure of the mixers for all harmonic impedance loading conditions. Each harmonic side band of frequencies contributing noise to the mixer output is associated with a set of noise parameters. A measurement method for extracting the noise parameters is described.
Abstract: PDI derivatives useful as opto-electronically active materials or for the synthesis of such materials. Certain compounds herein function as efficient electron acceptors and are useful as electron active components of electronic devices.
Type:
Grant
Filed:
June 6, 2017
Date of Patent:
January 9, 2018
Assignee:
UTI Limited Partnership
Inventors:
Arthur D. Hendsbee, Jon-Paul Sun, Gregory C. Welch, Ian G. Hill, Seth McAfee, Jonathan Cann
Abstract: The methods include selectively reducing or expanding T cells according to the antigenic specificity of the T cells. Therefore, the present invention can be used to reduce or eliminate pathogenic T cells that recognize autoantigens, such as beta cell specific T cells. As such, the present invention can be used to prevent, treat or ameliorate autoimmune diseases such as IDDM. Furthermore, the present invention can be used to expand desirable T cells, such as anti-pathogenic T cells to prevent, treat and/or ameliorate autoimmune diseases.
Type:
Application
Filed:
May 31, 2017
Publication date:
November 23, 2017
Applicants:
UTI Limited Partnership, The General Hospital Corporation
Abstract: This disclosure provides therapeutic compositions and methods for treating multiple sclerosis or a multiple sclerosis-related disorder in a subject in need thereof comprising administering an effective amount of an antigen-MHC-nanoparticle complex to the subject, wherein the antigen is a multiple sclerosis-related antigen.
Abstract: Metal-organic framework (MOF) materials particularly useful for adsorbing CO2. More specifically the MOF has pores and comprises zinc ions, oxalate, and a cycloazocarbyl compound. A preferred cycloazocarbyl compound is 1,2,4-triazolate. Methods for making the porous MOH and methods for using the porous MOH for adsorbing CO2.
Type:
Grant
Filed:
March 11, 2014
Date of Patent:
October 10, 2017
Assignee:
UTI Limited Partnership
Inventors:
George Shimizu, Ramanathan Vaidhyanathan, Simon Iremonger, Kyle Deakin, Jian-Bin Lin, Karl W. Dawson
Abstract: Systems and methods for inherent fast Time To First position Fix (TTFF) and high sensitivity are described. An embodiment of a method may include interpolating a satellite position in response to a navigation message having initial conditions for satellite ephemeris data converted into Keplerian format, wherein signal fixation is maintained in response to receiving the navigation signal at least once per day.
Abstract: Conventional cancer immunotherapy falls short at efficiently expanding T cells that specifically target cancerous cells in numbers sufficient to significantly reduce the tumor size or cancerous cell number in vivo. To overcome this limitation, provided herein are nanoparticles coated with MHC class I and/or class II molecules presenting tumor-specific antigens and co-stimulatory molecules and their use to expand antigen-specific anti-tumorigenic T cells to levels not achieved in current immunotherapeutic techniques. These antigen-specific anti-tumorigenic T cells include cytotoxic T cells, effector T cells, memory T cells, and helper T cells that are necessary to initiate and maintain a substantial immune response against metastatic or non-metastatic cancerous, pre-cancerous, or neoplastic cells in vivo. The present invention describes a systemic approach to targeting cancerous or pre-cancerous cells that are circulating cells, as in lymphomas, migratory metastatic cells, and solid tumors.
Abstract: The present invention relates to novel compounds, compositions containing same and methods for inhibiting STAT3 and/or STAT5 activity or for the treatment of a STAT3 or STAT5-dependent cancer using said compounds; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
Type:
Application
Filed:
March 30, 2017
Publication date:
September 21, 2017
Applicants:
The Governing Council of the University of Toronto, UTI Limited Partnership, Indiana University Research and Technology Corporation
Inventors:
Patrick Thomas Gunning, Sina Haftchenary, Brent David George Page, Samuel Weiss, Hema Artee Luchman, Melissa L. Fishel
Abstract: The present invention provides T-type calcium channel modulators and methods for producing and using the same. In some embodiments, compounds of the invention are of the formula: where R1 is selected from the group consisting of alkyl, alkenyl, polyether, alkoxy and cycloalkyl; X is selected from the group consisting of methylene, —C(?O)—[NR4]a, —C(?S)—, and —S(?O)b; R2 is selected from the group consisting of heterocycloalkyl and heteroaryl; R3 is selected from the group consisting of alkyl, alkenyl, polyether, alkoxy, cycloalkyl, —NR5R6, —C(?O)NR5R6, —C(?O)ORa (where Ra is alkyl, typically C1-C8 alkyl, often C2-C6 alkyl, and in one particular embodiment Ra is tert-butyl), and —SO2NR5R6; R4 is hydrogen, alkyl, or a nitrogen protecting group; each of R5 and R6 are independently selected from the group consisting of hydrogen and alkyl; a is 0 or 1; b is 1 or 2; n=1 to 3; and m=0 to 1.
Type:
Application
Filed:
October 15, 2015
Publication date:
August 17, 2017
Applicants:
UTI Limited Partnership, University of Montana
Abstract: A system and a method for producing biomass from a mixed community of algal species. The method comprises the steps of culturing the mixed community of at least two algal species as biofilms on transparent surfaces having structural features and an optical filter, providing a continuous supply of a culture medium comprising at least 0.5 mol/L aqueous (bi)carbonate and having a pH greater than 9. The method disclosed herein facilitates online monitoring of mixed community productivity by the quantification of oxygen production.
Type:
Application
Filed:
February 9, 2017
Publication date:
August 10, 2017
Applicant:
UTI Limited Partnership
Inventors:
Marc STROUS, Christine SHARP, Hector de la HOZ SIEGLER, Gregory WELCH